Why Is ADMA BIOLOGICS INC (ADMA) Stock Up Today?

ADMA Biologics shares surged 25.29% to close at $13.13, marking a significant move driven by a third-quarter earnings beat. The primary catalyst was strong demand for the company's flagship product, Asceniv, which propelled revenue and margins above expectations.

What Happened

The stock posted its best performance in ten months after the company reported better-than-expected financials for the third quarter of 2026. Management highlighted that Asceniv demand surged, driving margin expansion and prompting the company to raise its guidance. While the lead product performed well, BIVIGAM faced some pressure, and receivables lagged the target range. On the earnings call, the CEO stated that the star drug Asceniv is just getting started. Analysts responded positively to the results. Cantor Fitzgerald raised its price target to $13 from $12 while maintaining a Neutral rating. Canaccord also adjusted its outlook, raising its price target to $19 from $18.

What The Data Shows

The stock opened at $12.64, a 20.6% gap up from the prior close of $10.48. Trading volume reached 10.1 million shares, which is 3.7 times the three-month daily average. The session high was $13.77 at 12:45 PM ET, while the low was $11.87 at 9:25 AM ET. The company currently has a market cap of $2.5 billion with a P/E ratio of 15.0. Revenue grew 8.0% on a trailing twelve-month basis, and the net margin stands at 33.0%. The stock has a beta of 0.66 and trades within a 52-week range of $7.21 to $20.46. Over the last eight sessions prior to this move, the stock had declined 5.3%. The company printed 27 fresh 52-week highs on November 5, 2026. Recent congressional filings show Donald J. Trump sold between $1,001 and $15,000 on July 29, 2026, and bought between $15,001 and $50,000 on June 22, 2026.

What To Watch

Investors will monitor the company's ability to sustain the momentum in Asceniv sales and manage receivables as it moves into the next reporting period.